PALLEON PHARMACEUTICALS
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.
PALLEON PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.palleonpharma.com
Total Employee:
11+
Status:
Active
Contact:
(508)479-6358
Email Addresses:
[email protected]
Total Funding:
147.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Current Advisors List
Current Employees Featured
Founder
Investors List
Takeda Ventures
Takeda Ventures investment in Series B - Palleon Pharmaceuticals
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Palleon Pharmaceuticals
Matrix Capital Management
Matrix Capital Management investment in Series B - Palleon Pharmaceuticals
Vertex Ventures HC
Vertex Ventures HC investment in Series B - Palleon Pharmaceuticals
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Palleon Pharmaceuticals
Surveyor Capital
Surveyor Capital investment in Series B - Palleon Pharmaceuticals
SR One
SR One investment in Series B - Palleon Pharmaceuticals
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series A - Palleon Pharmaceuticals
Vertex Ventures
Vertex Ventures investment in Series A - Palleon Pharmaceuticals
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Palleon Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-06-09 | Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer |
| 2020-02-13 | Palleon Pharma Promotes Li Peng to Chief Scientific Officer |
Official Site Inspections
http://www.palleonpharma.com Semrush global rank: 4.76 M Semrush visits lastest month: 1.94 K
- Host name: 185.112.185.35.bc.googleusercontent.com
- IP address: 35.185.112.185
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Palleon Pharmaceuticals"
About Us – Palleon Pharmaceuticals
Jim Broderick is an accomplished biotech executive with more than 20 years of experience in the industry. He was Co-Founder and Chairman of Ra Pharmaceuticals (NASDAQ RARX, …See details»
Company Summary - Palleon Pharma
Jan 7, 2023 Investors: [email protected]. Title: PowerPoint Presentation Author: Nathan Matt Created Date: 1/7/2023 5:42:55 PM ...See details»
Overview, News & Similar companies - ZoomInfo.com
Palleon Pharmaceuticals contact info: Phone number: (857) 285-5900 Website: www.palleonpharma.com What does Palleon Pharmaceuticals do? Palleon Pharmaceuticals …See details»
Palleon Pharmaceuticals: Contact Details and Business Profile
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence …See details»
Palleon Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (508)479-6358 Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune …See details»
Working At Palleon Pharma: Company Overview and Culture - Zippia
Mar 14, 2024 palleonpharma.com. Organization Type. Private. CEO. Jim Broderick. Social Media. Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer …See details»
Palleon Pharmaceuticals CEO and Key Executive Team | Craft.co
Palleon Pharmaceuticals's Chief Executive Officer, Founder is Jim Broderick. Other executives include Li Peng, Chief Scientific Officer; David Feltquate, Chief Medical Officer and 2 others. …See details»
Palleon Pharma - MassBio
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence …See details»
Palleon Pharmaceuticals - LinkedIn
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence …See details»
Palleon Pharmaceuticals - PitchBook
Palleon Pharmaceuticals General Information Description. Developer of therapeutics designed to offer glycol-immune checkpoint inhibitors to treat cancer. The company's therapeutics are …See details»
Palleon Pharmaceuticals - Craft
Palleon Pharmaceuticals is a biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The Company’s proprietary Convergence Platform …See details»
Palleon Pharmaceuticals Appoints David Johnson to Its Board of ...
Nov 2, 2021 www.palleonpharma.com. Contacts. Palleon Media Contact Thomas Stephenson Ten Bridge Communications [email protected] (617) 448-1803 Contacts.See details»
Palleon Pharmaceuticals Raises $100 million Series B to Develop …
Sep 17, 2020 Learn more at www.palleonpharma.com. Contacts. Nichole Sarkis Ten Bridge Communications [email protected] 774-278-8273 Release Summary.See details»
Palleon Pharmaceuticals Appoints Li Peng, Ph.D., as Chief Scientific ...
WALTHAM, Mass., February 12, 2020 – Palleon Pharmaceuticals, a leading biotech company developing drugs that target the Siglec-Sialoglycan axis to treat cancer, today announced that …See details»
Palleon Co-Founder Dr. Carolyn Bertozzi wins a Nobel Prize in …
Jan 5, 2023 We're excited to share Palleon Pharmaceuticals scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.See details»
Palleon Pharmaceuticals Announces IND Clearance for First-in …
Jan 20, 2022 www.palleonpharma.com. Contacts. Palleon Media Contact Thomas Stephenson Ten Bridge Communications [email protected] (617) 448-1803 Contacts.See details»
News – Palleon Pharmaceuticals
Jun 22, 2023 November 8, 2024 Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at …See details»
Science & Approach – Palleon Pharmaceuticals
HYDRA Platform. Palleon has developed the powerful HYDRA platform to support our portfolio of cancer therapeutic candidates. HYDRA is an immunohistochemistry-based translational …See details»
Palleon Pharmaceuticals Announces First Patient Dosed in Phase …
Mar 8, 2022 www.palleonpharma.com. Contacts. Palleon Media Contact Thomas Stephenson Ten Bridge Communications [email protected] (617) 448-1803 Contacts.See details»